- $1.21bn
- $2.00bn
- $6.32bn
Annual income statement for Ardent Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4,870 | 5,130 | 5,409 | 5,966 | 6,324 |
| Cost of Revenue | |||||
| Gross Profit | 2,576 | 2,718 | 3,025 | 3,431 | 3,667 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 4,487 | 4,913 | 5,185 | 5,564 | 6,006 |
| Operating Profit | 384 | 217 | 224 | 402 | 318 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 296 | 311 | 152 | 363 | 286 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 245 | 265 | 129 | 300 | 230 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 154 | 189 | 53.9 | 210 | 136 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 154 | 189 | 53.9 | 210 | 136 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.307 | 0.285 | 0.331 | 1.61 | 1.26 |